SAN DIEGO, November 14, 2022 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has been named a BioSpace 2023 Best Place to Work.

BioSpace recognized 30 life sciences companies in the small employer category (less than 1,000 employees) as the most sought-after in the industry by the life sciences community. AnaptysBio was only one in 3 recognized in “Biotech Beach” (greater San Diego area/small employer). BioSpace considers each organization’s merits with particular emphasis on culture, leadership, career growth and development opportunities and innovation.

AnaptysBio is thrilled to have been included as a winner in the small employer category as this is a tremendous accomplishment when you consider how many biopharma companies are in this space.

“This award acknowledges the commitment we have made to ensure AnaptysBio provides our employees with an exceptional employee experience”, said Beth Mueller, senior vice president, People Resources. “It is also a recognition of our teams’ commitment to transform patient health by delivering innovative immunology therapeutics.”

About Biospace’s “Best Places to Work” List
BioSpace, the leading source for life sciences news and careers, list of Best Places to Work includes only 60 U.S. operating employers that have been recognized as the most sought-after in the industry by the life sciences community. Based on responses from over 2,000 life sciences professionals, respondents were asked to identify their top three most desirable biopharma companies, segmented by large (more than 1,000+ employees) and small (less than 1,000 employees) companies. Respondents were also asked to rate their top choice organizations on attributes including: compensation, innovation, career growth opportunities, leadership, culture, diversity, equity and inclusion, reputation, and flexibility and remote work.

About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our anti-PD-1 agonist program in Phase 2 for the treatment of moderate-to-severe alopecia areata; and ANB032, our anti-BTLA agonist program. AnaptysBio is also developing imsidolimab, our anti-IL-36R antibody in Phase 3 for the treatment of generalized pustular psoriasis, or GPP. We also have additional preclinical programs and discovery research of potentially innovative immunology therapeutics, including ANB033, an anti-CD122 antagonist antibody for the treatment of inflammatory diseases. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).

Contact:
Dennis Mulroy
AnaptysBio, Inc.
858.732.0201
dmulroy@anaptysbio.com